We are live on ! Find out more
AKRO icon

Akero Therapeutics

Delisted

AKRO was delisted on the 8th of December, 2025.

113 hedge funds and large institutions have $330M invested in Akero Therapeutics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

61% more call options, than puts

Call options by funds: $111K | Put options by funds: $69K

38% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 29

34% more capital inflows, than outflows

Capital inflows: $53.7M | Capital outflows: $40M

10% more funds holding

Funds holding: 103 → 113 (+10)

4.35% more ownership

Funds ownership: 100.52% → 104.87% (+4.4%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
113
Holders Change
+10
Holders Change %
+9.71%
% of All Funds
1.89%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
22
Increased
40
Reduced
29
Closed
10
Calls
$111​K
Puts
$69​K
Net Calls
+$42​K
Net Calls Change
+$501​K

AKRO Hedge Fund Activity: Q2 2022 in Review

113 of the 5,965 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2022, worth a combined $330M — down 34% from $499M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new AKRO positions and 10 closed out — a net gain of 12 holders — while 40 added to existing stakes and 29 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $10.5M. The largest seller was Wellington Management Group, cutting an estimated $16M.

  • 113 institutional investors held Akero Therapeutics (AKRO) as of Q2 2022, up from 103 in Q1 2022.
  • Funds reported $330M of Akero Therapeutics stock for Q2 2022, down 34% quarter-over-quarter.
  • 22 funds opened new Akero Therapeutics positions in Q2 2022 and 10 closed out, a net change of +12 holders.
  • The largest Akero Therapeutics buyer in Q2 2022 was Marshall Wace, an estimated $10.5M added.
  • The largest Akero Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $16M sold.

Based on aggregated 13F filings for Q2 2022.